Con la colaboración de:
En los últimos años, el tratamiento del colesterol LDL (c-LDL) ha dado un giro significativo, especialmente con la introducción de terapias innovadoras que buscan mejorar la adherencia y optimizar los resultados clínicos.
Lucía Matute repasa con Pedro Chinchurreta, Alejandro Gutiérrez Fernández y Alfonso Valle la evidencia en la práctica clínica real con inclisirán, terapia que ha demostrado una reducción eficaz y sostenida del c-LDL en los ensayos clínicos, con un buen perfil de seguridad en pacientes con alto riesgo cardiovascular.
Participantes:
Lucía Matute BlancoHospital Universitario Ramón y Cajal, Madrid
Pedro Chinchurreta CapoteHospital Universitario Costa del Sol, Marbella
Alejandro Gutiérrez FernándezHospital Universitario San Pedro, Logroño
Alfonso Valle MuñozHospital de Denia, Alicante
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805.. Rev Esp Cardiol (Engl Ed). 2016;69(1):11-18. doi:10.1016/j.rec.2015.06.015.
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387.
- Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials. Mayo Clin Proc. 2024 Jul 5:S0025-6196(24)00167-8. doi: 10.1016/j.mayocp.2024.03.025.
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058
- Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI study. Rev Clin Esp (Barc). 2025 Oct;225(8):502344. doi: 10.1016/j.rceng.2025.502344.
- Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024 Nov 11;31(15):1792-1803. doi: 10.1093/eurjpc/zwae199.
- Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023 Apr 5;29:100624. doi: 10.1016/j.lanepe.2023.100624.
- Preliminary results from REALITY: a nation-wide study of a database with 1.8 million “real-life” patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain. Presented at ESC Congress 2022. Barcelona, Spain
- Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry). J Am Coll Cardiol. 2025 Feb 11;85(5):536-540. doi: 10.1016/j.jacc.2024.10.106.
- A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months. Clin Med Insights Cardiol. 2025 May 11;19:11795468251337425. doi: 10.1177/11795468251337425.
- Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry. Cardiovasc Drugs Ther. 2025 Jul 15. doi: 10.1007/s10557-025-07749-3.
- LipidWise
